A GMP Protocol for the Manufacture of Tregs for Clinical Application

Alice O'Neil, Matthew Brook, Seetha Abdul-Wahab, Joanna Hester, Giovanna Lombardi, Fadi Issa

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)


Infusion of regulatory T cells is a promising therapeutic strategy in organ transplantation to modulate the immune system, prevent rejection, minimize the need for pharmaceutical immunosuppression, and improve long-term transplant outcomes. Here we describe a GMP-compliant method we have used for the manufacture of ex vivo expanded autologous regulatory T cells for use in clinical trials. [Abstract copyright: © 2023. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.]
Original languageEnglish
Pages (from-to)205-227
Number of pages23
JournalMethods in molecular biology (Clifton, N.J.)
Publication statusPublished - 2023


  • Regulatory T cells
  • Pharmaceutical Preparations
  • Tolerance
  • Immune Tolerance
  • Immunosuppression Therapy
  • Graft Rejection - prevention & control
  • Immunosuppression minimization
  • Treg
  • T-Lymphocytes, Regulatory
  • Transplantation
  • Organ Transplantation


Dive into the research topics of 'A GMP Protocol for the Manufacture of Tregs for Clinical Application'. Together they form a unique fingerprint.

Cite this